World News

The project is backed by a conditional grant of up to C$5 million (US$3.6 million) from the Ontario government through the Invest Ontario Fund.

Insulet received Investigational Device Exemption approval from the U.S. Food and Drug Administration in March 2026, clearing the way for the trial to begin.

The decision positions LANGLARA as only the fourth insulin glargine product available in the US market, joining established products commercialized by Novo Nordisk, Sanofi and Eli Lilly.

The tablet combines 100 mg of doravirine and 0.25 mg of islatravir in a once-daily formulation.

Photon Flash radiotherapy delivers radiation more than 100 times faster than conventional radiotherapy techniques, to reduce damage to surrounding healthy tissue while effectively targeting tumors.

If fully developed and commercialized, Huahui Health could receive up to US$1.9 billion in milestone-based payments, in addition to tiered royalties on future global sales.

The acquisition is expected to close by the end of the second quarter or early third quarter of 2026, pending regulatory approvals and customary closing conditions.

Through this expansion, the company aims to strengthen advanced manufacturing capabilities, support workforce development, and generate hundreds of construction-related jobs.

Thermo Fisher’s microbiology unit generated US$645 million in revenue in 2025 and operates within the company’s specialty diagnostics segment.

Terns has now become a wholly owned subsidiary of Merck, and its common stock has ceased trading on the Nasdaq Global Select Market.